Cargando…
MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
BACKGROUND: Cell-division cycle 20 (CDC20) is overexpressed in a variety of tumor cells and is negatively regulated by wild-type p53 (wtp53). Our previous study uncovered that CDC20 was upregulated and associated with poor outcome in diffuse large B-cell lymphoma (DLBCL) based on bioinformatics anal...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575066/ https://www.ncbi.nlm.nih.gov/pubmed/33116627 http://dx.doi.org/10.2147/OTT.S253758 |
_version_ | 1783597742028750848 |
---|---|
author | Sun, Chengtao Li, Mengzhen Feng, Yanfen Sun, Feifei Zhang, Li Xu, Yanjie Lu, Suying Zhu, Jia Huang, Junting Wang, Juan Hu, Yang Zhang, Yizhuo |
author_facet | Sun, Chengtao Li, Mengzhen Feng, Yanfen Sun, Feifei Zhang, Li Xu, Yanjie Lu, Suying Zhu, Jia Huang, Junting Wang, Juan Hu, Yang Zhang, Yizhuo |
author_sort | Sun, Chengtao |
collection | PubMed |
description | BACKGROUND: Cell-division cycle 20 (CDC20) is overexpressed in a variety of tumor cells and is negatively regulated by wild-type p53 (wtp53). Our previous study uncovered that CDC20 was upregulated and associated with poor outcome in diffuse large B-cell lymphoma (DLBCL) based on bioinformatics analysis. Dysregulation of the MDM2-p53 is a major mechanism to promote DLBCL. Thus, we hypothesized that CDC20 could be a downstream gene of the MDM2-p53 signaling pathway. However, the clinical significance and mechanistic role of a novel MDM2-p53-CDC20 signaling pathway in DLBCL have still remained unclear. MATERIALS AND METHODS: RT-qPCR was performed in MDM2 knocked down (KD) and control (Ctrl) OCI-Ly3/OCI-Ly10 cells to investigate whether CDC20 was a downstream gene of the MDM2-p53 pathway. The effects of CDC20 on cell proliferation, cell cycle and apoptosis were assessed, as well as the role of CDC20 in suppressing tumorigenicity in vivo. Furthermore, we also investigated the roles of CDC20 and MDM2 in progression of DLBCL and the underlying mechanisms. RESULTS: The results of RT-qPCR revealed that CDC20 was downregulated while TP53 was upregulated in MDM2 KD OCI-Ly3 and OCI-Ly10 cells. It was unveiled that the expression levels of CDC20 and MDM2 were upregulated in DLBCL tissues and cells, and high CDC20 expression was correlated with adverse clinical features and poor outcome. Functional assays showed that downregulation of CDC20 could inhibit proliferation, induce apoptosis and cell cycle arrest in vitro. In addition, inactivation of the MDM2-p53 pathway by downregulation of MDM2 restored wtp53 expression level and reduced CDC20 protein level in OCI-Ly3 and OCI-Ly10 cells. Besides, targeting CDC20 was found to suppress tumorigenesis of DLBCL in vivo. CONCLUSION: CDC20 was identified as a key downstream gene of the MDM2-p53 signaling pathway in DLBCL and may be used as a novel target gene to guide therapeutic applications. |
format | Online Article Text |
id | pubmed-7575066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75750662020-10-27 MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma Sun, Chengtao Li, Mengzhen Feng, Yanfen Sun, Feifei Zhang, Li Xu, Yanjie Lu, Suying Zhu, Jia Huang, Junting Wang, Juan Hu, Yang Zhang, Yizhuo Onco Targets Ther Original Research BACKGROUND: Cell-division cycle 20 (CDC20) is overexpressed in a variety of tumor cells and is negatively regulated by wild-type p53 (wtp53). Our previous study uncovered that CDC20 was upregulated and associated with poor outcome in diffuse large B-cell lymphoma (DLBCL) based on bioinformatics analysis. Dysregulation of the MDM2-p53 is a major mechanism to promote DLBCL. Thus, we hypothesized that CDC20 could be a downstream gene of the MDM2-p53 signaling pathway. However, the clinical significance and mechanistic role of a novel MDM2-p53-CDC20 signaling pathway in DLBCL have still remained unclear. MATERIALS AND METHODS: RT-qPCR was performed in MDM2 knocked down (KD) and control (Ctrl) OCI-Ly3/OCI-Ly10 cells to investigate whether CDC20 was a downstream gene of the MDM2-p53 pathway. The effects of CDC20 on cell proliferation, cell cycle and apoptosis were assessed, as well as the role of CDC20 in suppressing tumorigenicity in vivo. Furthermore, we also investigated the roles of CDC20 and MDM2 in progression of DLBCL and the underlying mechanisms. RESULTS: The results of RT-qPCR revealed that CDC20 was downregulated while TP53 was upregulated in MDM2 KD OCI-Ly3 and OCI-Ly10 cells. It was unveiled that the expression levels of CDC20 and MDM2 were upregulated in DLBCL tissues and cells, and high CDC20 expression was correlated with adverse clinical features and poor outcome. Functional assays showed that downregulation of CDC20 could inhibit proliferation, induce apoptosis and cell cycle arrest in vitro. In addition, inactivation of the MDM2-p53 pathway by downregulation of MDM2 restored wtp53 expression level and reduced CDC20 protein level in OCI-Ly3 and OCI-Ly10 cells. Besides, targeting CDC20 was found to suppress tumorigenesis of DLBCL in vivo. CONCLUSION: CDC20 was identified as a key downstream gene of the MDM2-p53 signaling pathway in DLBCL and may be used as a novel target gene to guide therapeutic applications. Dove 2020-10-15 /pmc/articles/PMC7575066/ /pubmed/33116627 http://dx.doi.org/10.2147/OTT.S253758 Text en © 2020 Sun et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sun, Chengtao Li, Mengzhen Feng, Yanfen Sun, Feifei Zhang, Li Xu, Yanjie Lu, Suying Zhu, Jia Huang, Junting Wang, Juan Hu, Yang Zhang, Yizhuo MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma |
title | MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma |
title_full | MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma |
title_fullStr | MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma |
title_full_unstemmed | MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma |
title_short | MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma |
title_sort | mdm2-p53 signaling pathway-mediated upregulation of cdc20 promotes progression of human diffuse large b-cell lymphoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575066/ https://www.ncbi.nlm.nih.gov/pubmed/33116627 http://dx.doi.org/10.2147/OTT.S253758 |
work_keys_str_mv | AT sunchengtao mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT limengzhen mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT fengyanfen mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT sunfeifei mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT zhangli mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT xuyanjie mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT lusuying mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT zhujia mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT huangjunting mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT wangjuan mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT huyang mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma AT zhangyizhuo mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma |